# Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

> **NCT03600649** · PHASE1 · UNKNOWN · sponsor: **Salarius Pharmaceuticals, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Ewing Sarcoma
- Myxoid Liposarcoma
- Sarcoma,Soft Tissue
- Desmoplastic Small Round Cell Tumor
- Extraskeletal Myxoid Chondrosarcoma
- Angiomatoid Fibrous Histiocytoma
- Clear Cell Sarcoma
- Primary Pulmonary Myxoid Sarcoma
- Myoepithelial Tumor
- Sclerosing Epithelioid Fibrosarcoma
- Fibromyxoid Tumor

## Interventions

- **DRUG:** Seclidemstat
- **DRUG:** Cyclophosphamide
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT03600649
- **Lead sponsor:** Salarius Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-04
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600649, "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03600649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*